Aprepitant is a Small Molecule owned by Merck & Co, and is involved in 59 clinical trials, of which 58 were completed, and 1 is ongoing.

Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).

The revenue for Aprepitant is expected to reach a total of $461m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Aprepitant NPV Report.

Aprepitant is currently owned by Merck & Co.

Aprepitant Overview

Aprepitant (Emend, Emend Tri-Pack) is aphenylmorpholine derivative acts as anti-emetic agent. It is formulated as hard gelatin capsules and powder for suspension for oral route of administration. Emend is indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy or cisplatin-based cancer chemotherapy in adults. Emend tri-pack (combination kit of 80 mg and 125 mg capsules) is given as part of combination therapy. It is prevention of postoperative nausea and vomiting (PONV) in adults. Emend is also indicated for use in combination with other antiemetic agents in patients 12 years of age and older and patients less than 12 years for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin, as well as for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Emend oral suspension in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associat ed with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin, nausea and vomiting associated with initial and repeat courses of moderately emetogenic  cancer chemotherapy (MEC). It was also under development for the treatment of major depressive disorder. Emend IV in combination with other antiemetic agents is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin and prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Merck & Co Overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.

Quick View – Aprepitant

Report Segments
  • Innovator (NME)
Drug Name
  • Aprepitant
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Toxicology
Key Companies
  • Sponsor Company: Merck & Co
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.